# Clearfield, Inc.: financial statements, quarterly

CLFD · Nasdaq · CIK 796505 · [Technology](/sectors/technology.md) · fiscal year ends Sep 30

Pages: [Overview](/companies/clfd.md) · [Financials](/companies/clfd/financials.md) · [Filings](/companies/clfd/filings.md) · [Insiders](/companies/clfd/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/clfd/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-09-30) | Q4 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [6.7 d](/filings/0001171843-25-007594.md) | [34.2](/filings/0001171843-25-000691.md) | [36.9](/filings/0001171843-25-003014.md) | [48.8](/filings/0001171843-25-005167.md) | [5.6 d](/filings/0001171843-25-007594.md) | [29.7](/filings/0001171843-26-000700.md) | [40.6](/filings/0001171843-26-003126.md) | [38.8](/filings/0001171843-26-005329.md) | [41.1 d](/filings/0001171843-25-007594.md) | [34.3](/filings/0001171843-26-000700.md) | [34.4](/filings/0001171843-26-003126.md) | [43.9](/filings/0001171843-26-005329.md) |
| Cost of revenue | $m | [0.1 d](/filings/0001171843-25-007594.md) | [29.5](/filings/0001171843-25-000691.md) | [34.1](/filings/0001171843-25-003014.md) | [38.1](/filings/0001171843-25-005167.md) | [(2.0) d](/filings/0001171843-25-007594.md) | [21.0](/filings/0001171843-26-000700.md) | [26.7](/filings/0001171843-26-003126.md) | [25.1](/filings/0001171843-26-005329.md) | [26.8 d](/filings/0001171843-25-007594.md) | [23.0](/filings/0001171843-26-000700.md) | [23.2](/filings/0001171843-26-003126.md) | [29.9](/filings/0001171843-26-005329.md) |
| Gross profit | $m | [6.6 d](/filings/0001171843-25-007594.md) | [4.7](/filings/0001171843-25-000691.md) | [2.8](/filings/0001171843-25-003014.md) | [10.7](/filings/0001171843-25-005167.md) | [7.6 d](/filings/0001171843-25-007594.md) | [8.7](/filings/0001171843-26-000700.md) | [14.0](/filings/0001171843-26-003126.md) | [13.7](/filings/0001171843-26-005329.md) | [14.2 d](/filings/0001171843-25-007594.md) | [11.4](/filings/0001171843-26-000700.md) | [11.2](/filings/0001171843-26-003126.md) | [13.9](/filings/0001171843-26-005329.md) |
| Selling, general and administrative | $m | [4.6 d](/filings/0001171843-25-007594.md) | [12.9](/filings/0001171843-25-000691.md) | [12.6](/filings/0001171843-25-003014.md) | [13.0](/filings/0001171843-25-005167.md) | [6.7 d](/filings/0001171843-25-007594.md) | [10.7](/filings/0001171843-26-000700.md) | [12.3](/filings/0001171843-26-003126.md) | [12.1](/filings/0001171843-26-005329.md) | [13.3 d](/filings/0001171843-25-007594.md) | [13.2](/filings/0001171843-26-000700.md) | [13.2](/filings/0001171843-26-003126.md) | [11.4](/filings/0001171843-26-005329.md) |
| Operating income | $m | [2.0 d](/filings/0001171843-25-007594.md) | [(8.2)](/filings/0001171843-25-000691.md) | [(9.7)](/filings/0001171843-25-003014.md) | [(2.3)](/filings/0001171843-25-005167.md) | [1.0 d](/filings/0001171843-25-007594.md) | [(2.0)](/filings/0001171843-26-000700.md) | [1.7](/filings/0001171843-26-003126.md) | [1.5](/filings/0001171843-26-005329.md) | [1.0 d](/filings/0001171843-25-007594.md) | [(1.8)](/filings/0001171843-26-000700.md) | [(2.1)](/filings/0001171843-26-003126.md) | [2.6](/filings/0001171843-26-005329.md) |
| Interest expense | $m | [0.3 d](/filings/0001171843-24-006402.md) | [0.1](/filings/0001171843-25-000691.md) | [0.1](/filings/0001171843-25-003014.md) | [0.2](/filings/0001171843-25-005167.md) | [0.1 d](/filings/0001171843-24-006402.md) | [0.1](/filings/0001171843-25-000691.md) | [0.1](/filings/0001171843-25-003014.md) | [0.1](/filings/0001171843-25-005167.md) | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.4 d](/filings/0001171843-25-007594.md) | [(1.0)](/filings/0001171843-25-000691.md) | [(2.1)](/filings/0001171843-25-003014.md) | [(0.3)](/filings/0001171843-25-005167.md) | [0.1 d](/filings/0001171843-25-007594.md) | [0.1](/filings/0001171843-26-000700.md) | [0.7](/filings/0001171843-26-003126.md) | [0.8](/filings/0001171843-26-005329.md) | [0.8 d](/filings/0001171843-25-007594.md) | [(0.0)](/filings/0001171843-26-000700.md) | [(0.2)](/filings/0001171843-26-003126.md) | [0.9](/filings/0001171843-26-005329.md) |
| Net income | $m | [2.7 d](/filings/0001171843-25-007594.md) | [(5.3)](/filings/0001171843-25-000691.md) | [(5.9)](/filings/0001171843-25-003014.md) | [(0.4)](/filings/0001171843-25-005167.md) | [(0.8) d](/filings/0001171843-25-007594.md) | [(1.9)](/filings/0001171843-26-000700.md) | [1.3](/filings/0001171843-26-003126.md) | [1.6](/filings/0001171843-26-005329.md) | [(9.1) d](/filings/0001171843-25-007594.md) | [(0.6)](/filings/0001171843-26-000700.md) | [(0.5)](/filings/0001171843-26-003126.md) | [3.0](/filings/0001171843-26-005329.md) |
| Diluted EPS | $ per share | not reported | [(0.35)](/filings/0001171843-25-000691.md) | [(0.40)](/filings/0001171843-25-003014.md) | [(0.04)](/filings/0001171843-25-005167.md) | not reported | [(0.13)](/filings/0001171843-26-000700.md) | [0.09](/filings/0001171843-26-003126.md) | [0.11](/filings/0001171843-26-005329.md) | not reported | [(0.04)](/filings/0001171843-26-000700.md) | [(0.04)](/filings/0001171843-26-003126.md) | [0.22](/filings/0001171843-26-005329.md) |
| Basic EPS | $ per share | not reported | [(0.35)](/filings/0001171843-25-000691.md) | [(0.40)](/filings/0001171843-25-003014.md) | [(0.04)](/filings/0001171843-25-005167.md) | not reported | [(0.13)](/filings/0001171843-26-000700.md) | [0.09](/filings/0001171843-26-003126.md) | [0.11](/filings/0001171843-26-005329.md) | not reported | [(0.04)](/filings/0001171843-26-000700.md) | [(0.04)](/filings/0001171843-26-003126.md) | [0.22](/filings/0001171843-26-005329.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-09-30) | FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [37.8](/filings/0001171843-24-006402.md) | [34.5](/filings/0001171843-24-000584.md) | [15.8](/filings/0001171843-24-002599.md) | [25.6](/filings/0001171843-24-004461.md) | [14.1](/filings/0001171843-25-007594.md) | [30.5](/filings/0001171843-25-000691.md) | [28.8](/filings/0001171843-25-003014.md) | [33.9](/filings/0001171843-25-005167.md) | [21.5](/filings/0001171843-26-005329.md) | [13.9](/filings/0001171843-26-000700.md) | [9.4](/filings/0001171843-26-003126.md) | [20.4](/filings/0001171843-26-005329.md) |
| Current assets | $m | [296](/filings/0001171843-24-006402.md) | [277](/filings/0001171843-24-000584.md) | [257](/filings/0001171843-24-002599.md) | [236](/filings/0001171843-24-004461.md) | [230](/filings/0001171843-25-007594.md) | [198](/filings/0001171843-25-000691.md) | [206](/filings/0001171843-25-003014.md) | [213](/filings/0001171843-25-005167.md) | [198](/filings/0001171843-26-005329.md) | [166](/filings/0001171843-26-000700.md) | [163](/filings/0001171843-26-003126.md) | [171](/filings/0001171843-26-005329.md) |
| Total assets | $m | [356](/filings/0001171843-24-006402.md) | [336](/filings/0001171843-24-000584.md) | [315](/filings/0001171843-24-002599.md) | [318](/filings/0001171843-24-004461.md) | [315](/filings/0001171843-25-007594.md) | [303](/filings/0001171843-25-000691.md) | [311](/filings/0001171843-25-003014.md) | [315](/filings/0001171843-25-005167.md) | [306](/filings/0001171843-26-005329.md) | [268](/filings/0001171843-26-000700.md) | [264](/filings/0001171843-26-003126.md) | [267](/filings/0001171843-26-005329.md) |
| Current liabilities | $m | [29.0](/filings/0001171843-24-006402.md) | [25.0](/filings/0001171843-24-000584.md) | [26.4](/filings/0001171843-24-002599.md) | [28.2](/filings/0001171843-24-004461.md) | [24.4](/filings/0001171843-25-007594.md) | [18.7](/filings/0001171843-25-000691.md) | [30.5](/filings/0001171843-25-003014.md) | [35.9](/filings/0001171843-25-005167.md) | [36.6](/filings/0001171843-26-005329.md) | [13.2](/filings/0001171843-26-000700.md) | [12.7](/filings/0001171843-26-003126.md) | [13.6](/filings/0001171843-26-005329.md) |
| Total liabilities | $m | [40.4](/filings/0001171843-24-006402.md) | [35.5](/filings/0001171843-24-000584.md) | [36.2](/filings/0001171843-24-002599.md) | [43.5](/filings/0001171843-24-004461.md) | [39.5](/filings/0001171843-25-007594.md) | [35.8](/filings/0001171843-25-000691.md) | [45.0](/filings/0001171843-25-003014.md) | [50.2](/filings/0001171843-25-005167.md) | [50.0](/filings/0001171843-26-005329.md) | [18.4](/filings/0001171843-26-000700.md) | [20.7](/filings/0001171843-26-003126.md) | [21.2](/filings/0001171843-26-005329.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | [2.2](/filings/0001171843-25-005167.md) | [2.1](/filings/0001171843-25-000691.md) | [0.0](/filings/0001171843-25-003014.md) | [0.0](/filings/0001171843-25-005167.md) | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | [2.1](/filings/0001171843-24-006402.md) | [2.2](/filings/0001171843-24-000584.md) | [2.2](/filings/0001171843-24-002599.md) | [0.0](/filings/0001171843-24-004461.md) | [0.0](/filings/0001171843-25-005167.md) | not reported | [2.2](/filings/0001171843-25-003014.md) | [2.4](/filings/0001171843-25-005167.md) | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [315](/filings/0001171843-25-007594.md) | [300](/filings/0001171843-25-003014.md) | [279](/filings/0001171843-25-005167.md) | [275](/filings/0001171843-25-005167.md) | [276](/filings/0001171843-26-005329.md) | [267](/filings/0001171843-26-003126.md) | [266](/filings/0001171843-26-005329.md) | [264](/filings/0001171843-26-005329.md) | [256](/filings/0001171843-26-005329.md) | [250](/filings/0001171843-26-003126.md) | [243](/filings/0001171843-26-005329.md) | [246](/filings/0001171843-26-005329.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:DebtCurrent, us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-09-30) | Q4 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [4.9 d](/filings/0001171843-24-006402.md) | [10.8](/filings/0001171843-25-000691.md) | [(5.7) d](/filings/0001171843-25-003014.md) | [4.0 d](/filings/0001171843-25-005167.md) | [13.1 d](/filings/0001171843-24-006402.md) | [7.2](/filings/0001171843-25-000691.md) | [3.0 d](/filings/0001171843-25-003014.md) | [7.9 d](/filings/0001171843-25-005167.md) | [8.4 d](/filings/0001171843-25-007594.md) | [(1.4)](/filings/0001171843-26-000700.md) | [(1.1) d](/filings/0001171843-26-003126.md) | [9.9 d](/filings/0001171843-26-005329.md) |
| Capital expenditure | $m | [1.2 d](/filings/0001171843-24-006402.md) | [2.4](/filings/0001171843-25-000691.md) | [2.0](/filings/0001171843-25-003014.md) | [1.2](/filings/0001171843-25-005167.md) | [4.0 d](/filings/0001171843-24-006402.md) | [2.1](/filings/0001171843-25-000691.md) | [2.4](/filings/0001171843-25-003014.md) | [0.4](/filings/0001171843-25-005167.md) | [0.3 d](/filings/0001171843-25-007594.md) | [1.0](/filings/0001171843-26-000700.md) | [1.0 d](/filings/0001171843-26-003126.md) | [0.9 d](/filings/0001171843-26-005329.md) |
| Share repurchases | $m | [0.0 d](/filings/0001171843-25-007594.md) | [12.2](/filings/0001171843-25-000691.md) | [15.6 d](/filings/0001171843-25-003014.md) | [5.6 d](/filings/0001171843-25-005167.md) | [0.0 d](/filings/0001171843-25-007594.md) | [6.3](/filings/0001171843-26-000700.md) | [4.7 d](/filings/0001171843-26-003126.md) | [5.7 d](/filings/0001171843-26-005329.md) | [(0.0) d](/filings/0001171843-25-007594.md) | [5.3](/filings/0001171843-26-000700.md) | [7.3 d](/filings/0001171843-26-003126.md) | [0.9 d](/filings/0001171843-26-005329.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities, us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment, us-gaap:PaymentsToAcquireProductiveAssets
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2023 (2022-12-31) | Q1 FY2023 (2023-03-31) | Q3 FY2023 (2023-06-30) | Q4 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [14.3](/filings/0001171843-24-000584.md) | [15.3](/filings/0001171843-24-002599.md) | [15.3](/filings/0001171843-24-004461.md) | [15.2](/filings/0001171843-25-000691.md) | [14.6](/filings/0001171843-25-003014.md) | [14.2](/filings/0001171843-25-005167.md) | [14.2](/filings/0001171843-26-000700.md) | [14.1](/filings/0001171843-26-003126.md) | [13.8](/filings/0001171843-26-005329.md) | [13.9](/filings/0001171843-26-000700.md) | [13.7](/filings/0001171843-26-003126.md) | [13.6](/filings/0001171843-26-005329.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 13,583,955 at 2026-07-31, from the cover of the [10-Q filed 2026-08-06](/filings/0001171843-26-005329.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:24 ET. No prices; not investment advice.